

Contributions 2023

Digestive Cancers Europe (DiCE) is open to funding from any public or private organisation, charity, foundation, or individual that shares DiCE's mission and vision. All contributions comply with the applicable legal requirements and ethical codes. Please see our Funding Guidelines for further details.

Grants are contributions to the organisation without specific requirements for project allocation.

Sponsorships are contributions for specific projects contractually agreed upon.

Educational grants are awarded through the process of competitive bids for a specific project proposal.

The '**services and consultancy**' category includes remunerated time invested by Digestive Cancers Europe staff and/or patients and carers to offer tailor-made services to public organisations and/or companies, such as participating in advisory boards, speaking at conferences, acting as a sounding board for the development of educational materials, etc.

The following overview specifies the funding received from our partners in 2023.


Sponsorships & grants	Amount in EUR
Amgen	40,000
Astellas	40,000
AstraZeneca	25,000
Bayer	2,500
BI	55,000
BMS	22,280
Daiichi-Sankyo	110,000
Jazz Pharmaceuticals	45,000
Merck	20,000
Olympus Europe	5,000
Pierre Fabre	20,000
MSD	35,000
Novartis	30,000
Roche	55,000
Sandoz	20,000
Servier	55,000
Takeda	20,000
Services & consultancy	19,822
Project grants*	80,000



**DIGESTIVE CANCERS
EUROPE**

EU funding (HORIZON EUROPE & EU4HEALTH projects)	333,607
Other projects (non-EU funded)	11,399
TOTAL	1,044,608

**In 2022, DiCE was awarded a project grant from BMS to develop the My DiCE Companion App. The project lasted 18 months, starting 1.1.2022 and ending 30.06.2023.*



Only funds contributed and received in 2023 to Digestive Cancers Europe are shown on the list.

Contributions agreed in 2023 and received in 2024 are not mentioned in the 2023 accounts; they will be included in the 2024 accounts.